Company intelligence / Profile preview

Systemic Therapeutics

Hamilton, Ontario, Canada

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Systemic Therapeutics is a Canadian pre-clinical biotechnology company developing first-in-class small molecule inhibitors of sterol regulatory element-binding proteins for metabolic disease. Its programs are designed to modulate lipid metabolism and reduce circulating proprotein convertase subtilisin/kexin type 9, with an initial focus on dyslipidemia and fatty liver disease. The company positions itself as a platform-driven developer of novel therapies for cardiometabolic disorders rather than a service provider. Based in Hamilton, Ontario, it appears to remain a private, independent company.

Therapeutic areas: CardiovascularGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Systemic Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Systemic Therapeutics.

Explore the full profile